Meine Aktien - 500 Beiträge pro Seite

[morchel]

z.Z. bekomme ich massenhaft Boardmailbezüglich verschiedener von mir vorgestellter Aktien! Ich beantworte auch normalerweise alle Mails (soferne ich sie nicht vergesse....sorry)

Hier eine Zusammenfassung meiner Gedanken über Alle!

LAMP: Am Besten ich halte meine Klappe, denn immer wenn ich sage: "der Boden ist gefunden", gehts noch weiter runter! Vieleicht hilft es was?? Bin noch immer der Ü*berzeugung, das die Firma auf das gröbste unterbewertet ist. Die NASDAQ Kiterien sind 4$ im Bid über einen Zeitraum von 1 Monat bei gleichzeitiger Mindestbewertung von 50 Mio USD sind aus meiner Sicht über einen Zeitraum von 12 Monaten zu schaffen!

NKCIF: steht meines Erachtens kurz vor dem Ausbruch und ist eine billige Kaufgelegenheit!

UDAT: gut bewertet aber mit reichlich platz nach oben!

GBSV: gefählich und verdächtig, BEOBACHTEN und Hype mitnehmen!

QNTI: da kommt Volumen rein! Gut bewertet aber dennoch schöne Gewinnchancen Möglich

ETEN: in den Klauen der MM. Volumen köännte heilsame Wirkung zeigen. Hat man gestern gesehen. Sobald die MM ein nachlassen des Volumens erkennen, wird geshortet. Die SEC und die Blackmoor Group sollten dem Treiben ein Ende setzen!

Donner Minerals: Hat sich wieder schön gefangen. Glaube das wir in der nächsten Zeit Kurse um 0,5CAD oder höher sehen werden!

FXSO: zeigt Stärke und bicht nicht ein! Bei vielen Leuten uaf der Watchlist die im geeigneten Monet reingehen werden!

OPTG: Schläft! ein schöner Kursgewinn kann kommen, wenn die Monatszahlen nur annähernd so gut sind wie die in den letzten Monaten!

APTD: Wenn das filing kommt, kanns wieder deutlich über 1 USD gehen!

morchel

[JavierOxtoa]

also bei einem Wert kommen mir bei deiner Prognose glatt die Tränen


Good Luck und liebe Grüsse trotzdem

Javi

[js200]

Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
Saturday, April 27, 2002
© 2002 Market Guide Inc. Data Provided by Market Guide Inc.
This report is provided for information purposes only. Under no circumstances is it
to be used or considered as an offer to sell, or a solicitation to buy any security.
While the information contained herein has been obtained from sources deemed
reliable, neither Market Guide nor any party through whom the reader obtains this
Report guarantees that it is accurate or complete or make any warranties with regard
to the results to be obtained from its use. All rights reserved. This report and its
contents may not be resold or otherwise used in commerce without the permission
of Market Guide, Inc.
2001 Marcus Ave. Suite South 200
Lake Success, NY 11042-1011
Tel: [phone] Fax: [phone]
Web Site: www.marketguide.com
Overview Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Fiscal Year ends December 31. All data are on a fiscal year basis except where noted. All financials
are reported to conform to the current year presentation and may reflect certain reclassifications
made in prior years.
Prepared Saturday, April 27, 2002 Page 2
Business Summary
L.A.M. Pharmaceutical Corp is engaged in the research and development of novel,
proprietary, long lasting injectable drugs and delivery systems for transdermal and
topical drugs.
Year-To-Date Results
For FY ended 12/31/01, revenues totaled $300K vs. none. Net loss rose 76% to $8.4M.
Revenues reflect a licensing agreement with Ixora Biomedical Company, Inc. Higher
loss reflects the expenses related to obtaining the equity LOC and stock option
compensations.
Share Information
Market Capitalization $21.8 Mil.
Shares Outstanding 22.0 Mil.
Trading Float 16.0 Mil.
Monthly Trading Volume 8.2 Mil.
Beta 2.3
Indicated Annual Dividend $0.00
Five Year Monthly Stock Performance History
Price information not available for L.A.M. Pharmaceutical.
Price History (Calendar Year)
High Price High
Low Price Low
Year End Price Close
Year End P/E P/E
Dividend Yield
High P/E High P/E
Low P/E Low P/E
2001
NA
NA
NA
NA
NA
NA
NA
2000
NA
NA
NA
NA
NA
NA
NA
1999
NA
NA
NA
NA
NA
NA
NA
1998
NA
NA
NA
NA
NA
NA
NA
1997
NA
NA
NA
NA
NA
NA
NA
YTD ’02
NA
NA
$0.99
NM
NA
NA
Current Price
Price (4/26/2002) $0.99
52 Week High (4/18/2002) $2.50
52 Week Low (1/22/2002) $0.44
Per Share Statistics & Current Price Multiples
Per Share Multiple
Earnings (TTM) ($0.54) NM
Book Value (MRQ) ($0.05) NM
Cash Flow (TTM) NA NM
Revenues (TTM) $0.02 52.1x
Employees
Employees 8
Sales Per Employee (TTM) $37,500
Net Income Per Employee (TTM) NM
TTM = Trailing Twelve Months, MRQ = Most Recent Quarter, NA = Not Available, NM = Not Meaningful, NAR = Not Available Due To A Restatement.
Stock Price Performance Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Prepared Saturday, April 27, 2002 Page 3
Institutional Ownership
NA Institutions own of the 22.0 million common shares outstanding.
The quick brown fox jumped over the lazy dog
Industry Overview Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Prepared Saturday, April 27, 2002 Page 5
Rochester Medical Corp. (ROCM) $28.8 $9.22 (27.5)% NM $5.40 $6.55 $3.50
IRIDEX Corporation (IRIX) $28.0 $28.5 0.4% 226.7x $4.08 $6.35 $3.18
Vascular Solutions, Inc. (VASC) $27.9 $11.8 NM NM $2.09 $10.30 $1.70
Paradigm Medical Indust. (PMED) $26.6 $7.71 NM NM $1.97 $3.54 $1.65
Cohesion Technologies (CSON) $26.2 $3.72 NM NM $2.77 $5.80 $1.70
Cambridge Heart, Inc. (CAMH) $25.4 $3.34 NM NM $1.31 $3.47 $1.00
Chad Therapeutics (CTU) $25.2 $17.9 (3.3)% NM $2.51 $4.35 $1.00
AMDL, Inc. (ADL) $25.1 $0.48 NM NM $3.03 $5.25 $1.78
Lakeland Industries, Inc (LAKE) $24.9 $76.7 2.0% 16.1x $9.26 $13.74 $3.94
Antares Pharma Inc. (ANTR) $24.7 $3.50 NM NM $2.70 $5.65 $1.59
BICO, Incorporated (BIKO) $24.5 $4.35 NM NM $0.01 $0.24 $0.01
Valley Forge Scientific (VLFG) $24.2 $5.46 8.1% 55.6x $3.00 $3.25 $1.70
Photoelectron Corporation (PHX) $23.8 $1.31 NM NM $2.39 $4.95 $2.00
Specialized Health Prod. (SHPI) $23.3 $0.63 NM NM $1.30 $2.09 $0.60
Avitar, Inc. (AVR) $23.2 $8.62 (56.4)% NM $0.58 $1.50 $0.50
American Medical Alert (AMAC) $22.8 $13.9 0.8% 205.9x $3.50 $3.93 $1.50
SpectraScience, Inc. (SPSI) $22.2 $0 NM NM $3.10 $7.94 $1.50
MedicalCV, Inc. (MDCVU) $22.0 $2.92 NM NM $2.80 $4.20 $2.75
L.A.M. Pharmaceutical (LAMP) $21.8 $0.30 NM NM $0.99 $2.50 $0.44
Lifestream Technologies (KFL) $21.4 $3.80 NM NM $1.00 $3.15 $0.99
BSD Medical Corporation (BSDM) $20.7 $2.94 5.4% 130.0x $1.17 $1.45 $0.60
Span-America Medical (SPAN) $20.7 $29.9 5.3% 13.3x $8.20 $8.25 $4.38
Vista Medical Technology (VMTI) $20.1 $9.33 (34.5)% NM $4.10 $5.00 $1.55
PLC Systems, Inc. (PLC) $19.0 $9.86 (30.3)% NM $0.64 $1.20 $0.41
Bio-Logic Systems Corp. (BLSC) $18.6 $28.6 4.2% 16.0x $4.45 $8.54 $3.75
Molecular Diagnostics, In (MCDG) $18.3 $0.88 NM NM $0.72 $1.50 $0.26
Encision, Inc. (ECSN) $17.3 $4.38 (6.5)% NM $3.20 $5.35 $0.85
Medstone International (MEDS) $17.2 $22.7 (2.9)% NM $4.37 $5.00 $3.10
Radiance Medical Systems (RADX) $17.1 $7.64 NM NM $1.30 $6.30 $0.90
Rockwell Medical Tech. (RMTI) $16.9 $9.02 (17.5)% NM $2.24 $3.18 $0.59
Andersen Group, Inc. (ANDR) $16.4 $32.9 (4.2)% NM $7.85 $13.00 $7.10
4-D Neuroimaging (FDNX) $16.0 $9.82 (50.0)% NM $0.11 $0.22 $0.08
Aristotle Corp. (ARTL) $15.6 $9.20 5.1% 32.7x $8.05 $9.36 $3.65
Magna-Lab, Inc. (MAGLA) $14.9 $0 NM NM $0.20 $0.60 $0.10
Genetronics Biomedical (GEB) $13.8 $4.71 NM NM $0.41 $1.70 $0.37
Horizon Medical Products (HMP) $13.8 $59.1 (8.7)% NM $1.03 $1.85 $0.43
Medical Equipment & Supplies Industry
Following is a list of companies in the Medical
Equipment & Supplies industry not appearing in the
chart above. They are listed in order of descending
market capitalization: MDT, BAX, GDT, SYK, BSX, BDX,
LUX, BMET, STJ, ZMH, SNN, PDCO, XRAY, VAR, BCR,
AOT, HSIC, BOL, STE, DP, RMD, PHCC, IVC, RESP,
ARRO, THER, SM, MNTR, EYE, AH, HAE, COO, IMDC,
SYD, AMMD, OCLR, PSSI, OMI, CNMD, WMGI, CRY, ...,
ROCM, ..., HMP, ....
LAMP is in the Medical Equipment & Supplies Industry of the Healthcare Sector. Below is a list
of the 35 companies most similar to LAMP’s market capitalization in the Medical Equipment &
Supplies Industry listed in descending order. There are 304 companies in this industry.
LAMP Price Perf. vs. Medical Equipment & Supplies Industry
LAMP vs. Co. Rank Industry
Period Actual S&P 500 In Industry Rank
4 Week 15.1% 22.7% 91 42
13 Week 94.1% 104.4% 97 25
26 Week 57.1% 61.3% 88 24
52 Week (38.5)% (28.4)% 30 57
YTD 73.7% 85.3% 94 22
Ranks are Percentile Ranks ranging from 0 to 99, with 99 = best.
Company Name Market TTM Net P/E Price 52-Week 52-Week
(Ticker Symbol) Cap. Revenue Margin 4/26/02 4/26/02 High Low
(Millions) (Millions)
The quick brown fox jumped over the lazy dog
The quick brown fox jumped over the lazy dog
The quick brown fox jumped over the lazy dog
The quick brown fox jumped over the lazy dog
Quarterly Trends Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Years are Fiscal Years
Prepared Saturday, April 27, 2002 Page 4
Quarterly Revenue
$ USD Billions
Quarterly EPS
Primary
Price/ TTM Sales Bands Price/ TTM Earnings Bands
The average institutional ownership of the Medical Equipment &
Supplies Industry is 36.9%, and the average institutional ownership of
the S&P 500 as a whole is 60.7%.
Insider Trading
Insiders hold 5.98 million shares. Insider trading
activity for the last 6 months is not available.
Daily Trading Activity During Last Four Months
Price information not available for L.A.M. Pharmaceutical.
Equity and Debt Composition
Common Stock $.0001 Par, 3/02, 50M auth., 21,982,705 issd. Insiders
own 27%. 9/98, 6M shares issued in a reverse acquisition with LAM
Pharmaceutical LLC.
Analyst Footnotes
FY’99,’00 fncls and ’01 Q’s are being reclassified.
Dividends
LAMP does not currently pay a dividend.
Officers
Joseph T. Slechta, Pres./COO
Peter Rothbart MD, Treas.
Gary M. Nath, Secy.
Headquarters
800 Sheppard Avenue West
Commercial Unit 1
Toronto, ON M3H 6
Company incorporated in 1998 in DE
Phone [phone]
Fax [phone]
Industry Valuation Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
S&P 500 Industry
Low
Industry
High
Industry
Average
LAMP
Prepared Saturday, April 27, 2002 Page 6
Price / Earnings Ratios
Current P/E NM 44.5x 411.3x 0.0x 29.3x
High P/E - Last 5 Years NA 77.0x 250.0x 15.8x 50.0x
Low P/E - Last 5 Years NA 23.2x 33.0x 2.5x 17.6x
Beta - 5 Yr. Monthly Avg. 2.3 0.6 7.3 (19.8) 1.0
Other Valuation Multiples
Price to Cash Flow (TTM) NM 33.6x 337.3x 0.0x 22.1x
Price to Free Cash Flow (TTM) NM 42.6x 420.0x 0.0x 35.4x
Price to Sales (TTM) 52.2x 5.3x 394.0x 0.0x 3.4x
Price to Book (MRQ) NM 6.9x 83.5x 0.0x 5.1x
Price to Tangible Book (MRQ) NM 18.2x 100.0x 0.0x 7.9x
Dividends
Dividend Yield 0.0% 0.7% 22.0% 0.0% 1.8%
5 Year Average Yield NM 0.6% 22.0% 0.0% 1.3%
5 Year Dividend Growth Rate NM 1.9% 25.2% (100.0)% 8.2%
Payout Ratio (TTM) 0.0% 26.7% 107.4% 0.0% 30.5%
Revenue Growth (TTM)
-100% 0% 100% 200%
Earnings (TTM) / Price
-30% -15% 0% 15%
APOA
MDSC
LECT
CAMY
MOYC
WRPC
SPTM
NYER ESMC
PDEX
HRT
DYNT
IMCI
BZET
MDWV
CHDX
ZVXI NIMU
MDTY
MXON
BOVI
STEN
MAGLA
ARTL
ANDR
RMTI
MEDS
ECSN
BLSC
PLC
VMTI
SPAN
BSDM
SPSI
AMAC
SHPI
VLFG
LAKE
ADL(235%)
CTU CAMH
IRIX
ROCM
CDIK
OSTX
MMD
CPCF
SMTS
SCHK
CCEL
GAIT
EPMD
AICX
CGCP
BJCT
AHPI
VSCI
MEDM
ATSI
CMED IFLO
CLZR
ATRI
CLN IMDS
ENMC
CXIM
BMED(462%)
BINX PHAR
SAFE TTG BCRL
REHB
CRDM
CURN
BVAS
BSMD
FONR
SPRX
IMX NMTI(24%)
UTMD
Industry Comparison of Revenue
Growth and Earnings Yield
Companies that exhibit both a high
earnings yield and high revenue growth
are generally more attractive than
companies with low revenue growth and
low earnings yield.
Companies for this scatter plot have a
market capitalization between $4 million
and $80 million. Companies with NA or
NM values do not appear.
EDAP has been excluded because of
Earnings Yield greater than 15%.
QQQQ, DCTH, DYX, SRGL, POSC, TMED,
MHLX, CRII, BPXS, OPSI, SNRSE, PHYX,
MS, SMPX, PMTI, IJX, HDII, HMP, GEB,
FDNX, RADX, MCDG, KFL, LAMP, AVR,
PHX, BIKO, ANTR, CSON, PMED, VASC,
AEGN, RBOT, SRMI, WHRT, PHMD,
VITA, CIO, BABY have been excluded
because of Earnings Yield less than
-30%.
QQQQ, IJX, KFL, BIKO, ANTR, PHMD,
VITA have been excluded because of
Revenue Growth greater than 200%.
TTM Revenue Quintile
0-20 21-40 41-60 61-80 81-100
Ratios for L.A.M.
Pharmaceutical use the
April 26 closing price of
$0.99.
L.A.M. Pharmaceutical
trades at a higher
multiple of sales than the
industry average.
This page compares selected valuation measures for LAMP with other companies in the Medical
Equipment & Supplies Industry as well as the S&P 500.
Industry Profitability Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
S&P 500 Industry
Low
Industry
High
Industry
Average
LAMP
Prepared Saturday, April 27, 2002 Page 7
Growth Rates
Revenue (MRQ) vs. Qtr 1 Yr. Ago NM 14.6% 495.5% (100.0)% (1.3)%
Revenue (TTM) vs. TTM Last Year (100.0)% 12.6% 2,630.9% (100.0)% 2.3%
Revenue 5 Year Growth Rate 10.7% 16.5% 600.7% (100.0)% 12.6%
EPS (MRQ) vs. Qtr 1 Yr. Ago 72.1% 17.5% 844.4% (632.7)% 4.7%
EPS (TTM) vs. TTM 1 Yr. Ago NM (7.2)% 517.9% (100.0)% (6.7)%
EPS - 5 Yr. Growth Rate NM 13.9% 190.8% (49.6)% 8.1%
Dividend - 5 Yr. Growth Rate NM 1.9% 25.2% (100.0)% 8.2%
Capital Spending - 5 Yr. Growth NM 18.5% 244.6% (100.0)% 10.2%
Revenue Growth (TTM)
-100% 0% 100% 200%
EBITD Margin (TTM)
-1000% -750% -500% -250% 0% 250%
APOA
LECT
CAMY
MOYC WRPC
DYX
SRGL
POSC
SPTM
TMED
MHLX CRII
BPXS
OPSI
NYER
SNRSE
ESMC
PDEX
HRT
DYNT
PHYX
MDWV
CHDX
MS
ZVXI
SMPX
NIMU
PMTI
MDTY
EDAP
HDII
BOVI
STEN
HMP
GEB
ARTL
FDNX ANDR
RMTI
RADX
MEDS
ECSN
MCDG(-1725%)
BLSC
PLC
VMTI
SPAN
BSDM
LAMP(-2728%)
AMAC
AVR
SHPI
PHX
VLFG
LAKE
ADL(235%)
CTU CAMH
CSON
PMED
VASC
IRIX
ROCM
OSTX
MMD SMTS
SCHK
CCEL
GAIT
AEGN(-1448%)
EPMD
AICXIMCI
RBOT
SRMI
CGCP
BJCT
AHPI
VSCI
MEDM
WHRT
ATSI CMED IFLO
PHMD(388%)
CLZR
ATRI
ENMC
CXIM
BMED(462%)
BINX
PHAR SAFE
TTG
BCRL
REHB
CRDM
CURN
CIO(-2085%)
BVAS
BSMD
FONR
SPRX
BABY
IMX
NMTI UTMD
Industry Comparison of Revenue
Growth and EBITD Margin (Earnings
Before Interest, Taxes, and
Depreciation / Revenues)
Companies with higher than average
EBITD margin and revenue growth are
doing well. Companies with a low
EBITD margin and revenue growth are
suffering.
Companies for this scatter plot have a
market capitalization between $4 million
and $80 million. Companies with NA or
NM values do not appear.
IJX, MXON have been excluded because
of EBITD Margin less than -1,000%.
QQQQ, IJX, KFL, BIKO, ANTR, VITA have
been excluded because of Revenue
Growth greater than 200%.
TTM Revenue Quintile
81-100% > $28.5 million
61-80% $13.9-28.5 million
41-60% $7.54-13.9 million
21-40% $3.15-7.54 million
0-20% < $3.15 million
LAMP’s 5-year revenue
growth is slower than the
industry average.
Industry Returns Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
S&P 500 Industry
Low
Industry
High
Industry
Average
LAMP
Prepared Saturday, April 27, 2002 Page 8
Financial Strength
Quick Ratio (MRQ) 0.1 1.3 98.5 0.0 1.1
Current Ratio (MRQ) 0.3 2.0 102.3 0.0 1.7
LT Debt/Equity (MRQ) NM 0.4 58.8 0.0 0.7
Total Debt/Equity (MRQ) NM 0.6 63.0 0.0 1.1
Interest Coverage (TTM) (35.2) 13.6 1,254.7 (4,415.8) 8.1
Management Effectiveness
LAMP’s TTM return on
assets is lower than the
industry average.
Return On Assets (TTM) (444.5)% 8.2% 86.6% (4,367.6)% 5.6%
Return On Assets - 5 Yr. Avg. (270.4)% 8.1% 18.5% (1,995.1)% 7.9%
Return On Investment (TTM) NM 12.2% 366.7% (862.2)% 9.2%
Return On Investment - 5 Yr. Avg. NA 11.7% 142.4% (919.4)% 12.6%
Return On Equity (TTM) NM 15.8% 222.3% (498.5)% 16.6%
Return On Equity - 5 Yr. Avg. NA 16.6% 32.1% (1,431.3)% 21.5%
Profit Margin (TTM)
0% 10% 20% 30%
Effective Tax Rate (TTM)
0% 15% 30% 45%
LECT(-2%)
SPTM
NYER
ESMC
HRT
DYNT
MDTY
EDAP
ARTL
BLSC
SPAN BSDM
AMAC(65%)
VLFG
LAKE
CCEL
IFLO
ATRI
ENMC
SAFE
REHB BVAS
NMTI(50%)
UTMD
Industry Comparison of Profit
Margin vs. Effective Tax Rate
Earnings of companies with below
average tax rates might erode if the tax
rate increases.
Companies for this scatter plot have a
market capitalization between $4 million
and $80 million. Companies with NA or
NM values do not appear.
LAMP does not appear because of an NA
or NM value.
TTM Revenue Quintile
81-100% > $42.7 million
61-80% $28.6-42.7 million
41-60% $16.8-28.6 million
21-40% $10.1-16.8 million
0-20% < $10.1 million
Industry Growth Rates Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
S&P 500 Industry
Low
Industry
High
Industry
Average
LAMP
Prepared Saturday, April 27, 2002 Page 9
Profitability Ratios
Gross Margin (TTM) 100.0% 59.7% 100.0% (99.7)% 46.4%
Gross Margin - 5 Yr. Avg. NA 59.3% 100.0% (59.7)% 47.5%
EBITD Margin (TTM) NM 19.1% 41.6% (98.4)% 19.6%
EBITD Margin - 5 Yr. Avg. NA 20.9% 54.6% (99.6)% 21.7%
Operating Margin (TTM) NM 15.4% 40.5% (97.9)% 16.0%
Operating Margin - 5 Yr. Avg. NA 15.6% 34.8% (95.6)% 18.0%
Pretax Margin (TTM) NM 15.7% 56.7% (97.5)% 13.6%
Pretax Margin - 5 Yr. Avg. NA 14.9% 99.1% (95.0)% 17.1%
Profit Margin (TTM) NM 9.8% 49.8% (97.5)% 8.4%
Profit Margin - 5 Yr. Avg. NA 9.1% 39.8% (92.7)% 11.2%
Effective Tax Rate (TTM) NM 35.9% 117.9% 0.0% 33.6%
Effective Tax Rate - 5 Yr. Avg. NM 38.4% 93.8% 0.0% 35.8%
Operating Efficiency
LAMP’s revenue per
employee is lower than
the industry average.
Revenue/Employee (TTM) $37,500 $231,335 $1,913,636 $605 $502,973
Net Income/Employee (TTM) NM $26,747 $97,457 $0 $77,333
Receivable Turnover (TTM) 0.5x 5.6x 860.8x 0.0x 9.7x
Inventory Turnover (TTM) 0.0x 3.0x 66.1x 0.0x 10.3x
Asset Turnover (TTM) 0.2x 0.9x 6.1x 0.0x 1.0x
Profit Margin (TTM)
-75% -50% -25% 0% 25%
Profit Margin (5-Yr. Avg.)
-80% -60% -40% -20% 0% 20%
APOA LECT
CAMY
MOYC
WRPC
SRGL(-85%)
SPTM
TMED
NYER
ESMC
PDEX
HRT
DYNT
IMCI
CHDX
ZVXI
NIMU(-93%)
PMTI
MDTY
EDAP(30%)
BOVI
STEN
HMP
ANDR
RMTI
MEDS
BLSC
SPAN
BSDM
AMAC
VLFG
LAKE
CTU
IRIX
ROCM
OSTX(-89%)
MMD
SCHK
GAIT
EPMD
AICX
RBOT(-92%)
SRMI(-93%)
AHPI
VSCI
MEDM
ATSI
CMED
IFLO
CLZR
ATRI
ENMC
CXIM
BINX
SAFE
TTG
REHB BVAS
FONR(40%)
BABY
IMX
NMTI(50%) UTMD Industry Comparison of Profit
Margin (TTM) vs. Profit Margin
(5-Yr. Avg)
Companies with TTM profit margins
above their 5-year average are
improving their profitability.
Companies for this scatter plot have a
market capitalization between $4 million
and $80 million. Companies with NA or
NM values do not appear.
LAMP does not appear because of an NA
or NM value.
TTM Revenue Quintile
81-100% > $42.7 million
61-80% $26.0-42.7 million
41-60% $15.5-26.0 million
21-40% $9.93-15.5 million
0-20% < $9.93 million
LAMP’s TTM gross
margin is higher than the
average for the industry.
Annual Income Statement
Annual Financials Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Years are Fiscal Years
In Thousands, Except Per Share Amounts (Currency is U.S. Dollars)
12 Months
Dec 31 1997
1997
12 Months
Dec 31 1998
1998
12 Months
Dec 31 1999
1999
12 Months
Dec 31 2000
2000
12 Months
Dec 31 2001
2001
Prepared Saturday, April 27, 2002 10
Revenues $200 $0 $0 $0 $300
Research/Development $434 $41 $185 $317 $480
Selling/Gen./Administration 154 190 380 1,317 1,581
Interest Expense 99 104 121 292 233
Conv. Premium 0 0 1,252 2,395 1,058
Depreciation/Amort. 13 3 11 36 27
Warrants- ELOC 0 0 0 0 1,100
Option-Officers 0 0 526 448 4,266
Total Expenses $700 $338 $2,475 $4,805 $8,745
Interest Income 0 2 3 28 45
Inv. in Affiliate 0 (122) (85) 0 0
Income Before Taxes ($500) ($458) ($2,557) ($4,777) ($8,400)
Income After Taxes ($500) ($458) ($2,557) ($4,777) ($8,400)
EPS Reconciliation
Adjusted Income Available to Common ($500) ($458) ($2,557) ($4,777) ($8,400)
Primary/Basic Average Sh 6,000 10,048 10,393 10,893 15,817
Pri/Bas EPS Ex. Extraordinary Items ($0.08) ($0.05) ($0.25) ($0.44) ($0.53)
Net Income ($500) ($458) ($2,557) ($4,777) ($8,400)
Pri/Bas EPS In. Extraordinary Items ($0.08) ($0.05) ($0.25) ($0.44) ($0.53)
Diluted Average Shs. 6,000 10,048 10,393 10,893 15,817
Diluted EPS Excl Extraordinary Items ($0.08) ($0.05) ($0.25) ($0.44) ($0.53)
Diluted EPS Incl Extraordinary Items ($0.08) ($0.05) ($0.25) ($0.44) ($0.53)
Gross Margin
97
100.0%
98
NM
99
NM
00
NM
01
100.0%
Revenue
97
$200
98
$0
99
$0
00
$0
01
$300
EPS Fully Diluted
97
($ 0.08)
98 ($ 0.05)99
($ 0.25)
00
($ 0.44)
01
($ 0.53)
Excl. Extraordinary Items
Fully Diluted Avg. Shrs.
Millions
97
6.0
98
10.0
99
10.4
00
10.9
01
15.8
Pretax Margin
97
(250.0)%
98
NM
99
NM
00
NM
01
(2,800.0)%
EBITD Margin
97
(194.0)%
98
NM
99
NM
00
NM
01
Annual Balance Sheet
Annual Financials Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Years are Fiscal Years
In Thousands (Currency is U.S. Dollars)
As of
Dec 31 1997
1997
As of
Dec 31 1998
1998
As of
Dec 31 1999
1999
As of
Dec 31 2000
2000
As of
Dec 31 2001
2001
Prepared Saturday, April 27, 2002 Page 11
Assets
Cash/Equivalents NA $411 $559 $1,546 $11
Cash Held Broker NA 0 465 357 0
Note Receivable NA 0 50 0 0
Accounts Rcvbl. NA 114 75 75 44
Raw Materials NA 0 0 121 98
Inv. Affiliate NA 85 0 0 0
Prepaid Expenses NA 5 0 3 5
Total Current Assets NA $615 $1,149 $2,102 $158
Furn./Fixtures NA $25 $26 $37 $122
Computer Equipment NA 0 3 9 22
Leasehold NA 10 10 11 31
Depreciation NA (31) (34) (38) (54)
Patents/Trademk. NA 74 232 336 489
Total Assets NA $693 $1,386 $2,457 $768
Liabilities
Payable/Accrued NA $53 $112 $397 $602
Convertible Debt NA 0 1,252 1,598 0
Deposit NA 125 0 0 0
Note Payable NA 5 0 0 0
Total Current Liabs NA $183 $1,364 $1,995 $602
Total Long Term Debt NA $0 $0 $0 $0
Due to Stkholder NA $1,267 $1,391 $1,256 $848
Deferred Royalty NA 207 207 207 207
Total Liabilities NA $1,657 $2,962 $3,458 $1,657
Shareholder Equity
Common Stock NA $1 $1 $1 $2
Paid in Capital NA 1,515 3,461 8,812 17,964
Accum. Deficit NA (2,481) (5,038) (9,815) (18,214)
Loan Rcvbl-Offic NA 0 0 0 (640)
Total Equity NA ($965) ($1,576) ($1,002) ($888)
Total Liab. & Sh. Equity NA $692 $1,386 $2,456 $769
Shares Outstanding NA 10,333 10,393 13,999 19,785
Total Cash and Equivs.
97
NA
98
$411
99
$1,024
00
$1,903
01
$11
Total Liabilities
97
NA
98
$1,657
99
$2,962
00
$3,458
01
$1,657
Total Equity
97
NA
98
($ 965)
99
($ 1,576)
00
($ 1,002)
01
($ 888)
Shares Outstanding
Millions
97
NA
98
10.3
99
10.4
00 14.0 01
19.8
Annual Cash Flow Statement
Annual Financials Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Years are Fiscal Years
In Thousands of U.S. Dollars
12 Months
Dec 31 1997
1997
12 Months
Dec 31 1998
1998
12 Months
Dec 31 1999
1999
12 Months
Dec 31 2000
2000
12 Months
Dec 31 2001
2001
Prepared Saturday, April 27, 2002 Page 12
Cash From (Used By) Operations
Net Income ($500) ($459) ($2,558) ($4,777) ($8,399)
Depreciation 13 3 11 36 27
Options/Awards 377 0 526 448 4,266
Conv. Premiums 0 0 1,252 2,395 1,058
Interest Expense 99 104 108 108 113
Inv. Affiliates 0 122 85 0 0
Notes Receivable 0 0 0 50 0
Accounts Receivable (200) 86 39 0 31
Inventory 0 0 0 (121) 23
Prepaid Expenses (2) (3) 5 (3) (3)
Payable/Accrued 49 (4) 59 151 204
Due to Stockholders 86 97 124 0 0
Warrants Issued 0 0 0 0 1,100
Int.-Converted Debt 0 0 0 151 121
Cash From Operations ($78) ($54) ($349) ($1,562) ($1,459)
Plus: Cash From (Used by) Investment Activities
Capital Expenditures $0 ($1) ($4) ($38) ($113)
Patents/Trademarks (27) (31) (166) (117) (169)
Cash From Investing ($27) ($32) ($170) ($155) ($282)
Plus: Cash From (Used By) Financing Activities
Capital Contribution $111 $0 $0 $0 $0
Common Stock 0 379 60 0 0
Note Payable, Net 2 3 (5) 0 0
Proc. Conv. Debt 0 125 1,077 2,406 (109)
Distributions (30) (39) 0 0 0
Exercise Options 0 0 0 189 112
Sale of Share-ELOCA 0 0 0 0 484
Loans Rcvbl-Officers 0 0 0 0 (640)
Cash From Financing $83 $468 $1,132 $2,595 ($153)
Equals: Increase (Decrease) In Cash
Net Change In Cash ($22) $381 $613 $879 ($1,892)
Free Cash Flow ($78) ($55) ($353) ($1,600) ($1,572)
Cash From Operations
97
98
99
($ 349)
00
($ 1,562)
01
($ 1,459)
Total Capital Expend.
97
98
99
($ 4)
00
($ 38)
01
($ 113)
Cash From Financing
97
98
99
$1,132
00
$2,595
01
($ 153)
Net Change In Cash
97
98
99
$613
00
$879
01
($ 1,892)
Quarterly Income Statement
Quarterly Financials Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Years are Fiscal Years
In Thousands, Except Per Share Amounts (Currency is U.S. Dollars)
3 Months
Dec 31 2000
Q4 ’00
3 Months
Mar 31 2001
Q1 ’01
3 Months
Jun 30 2001
Q2 ’01
3 Months
Sep 30 2001
Q3 ’01
3 Months
Dec 31 2001
Q4 ’01
Prepared Saturday, April 27, 2002 Page 13
Revenues $0 $0 $300 $0 $0
Research/Development $69 $60 $81 $193 $146
Selling/Gen./Administration 763 440 370 350 421
Warrants Issued-LOC 0 1,100 0 0 0
Depreciation 14 7 10 11 (1)
Other Operating 448 0 714 2,840 712
Conv. Premium 2,035 0 0 777 281
Interest Expense 113 61 61 82 29
Total Expenses $3,442 $1,668 $1,236 $4,253 $1,588
Interest Income 8 1 21 18 5
Income Before Taxes ($3,434) ($1,667) ($915) ($4,235) ($1,583)
Income After Taxes ($3,434) ($1,667) ($915) ($4,235) ($1,583)
EPS Reconciliation
Adjusted Income Available to Common ($3,434) ($1,667) ($915) ($4,235) ($1,583)
Primary/Basic Average Sh 11,858 14,036 14,241 15,367 19,625
Pri/Bas EPS Ex. Extraordinary Items ($0.29) ($0.12) ($0.06) ($0.28) ($0.08)
Net Income ($3,434) ($1,667) ($915) ($4,235) ($1,583)
Pri/Bas EPS In. Extraordinary Items ($0.29) ($0.12) ($0.06) ($0.28) ($0.08)
Diluted Average Shs. 11,858 14,036 14,241 15,367 19,625
Diluted EPS Excl Extraordinary Items ($0.29) ($0.12) ($0.06) ($0.28) ($0.08)
Diluted EPS Incl Extraordinary Items ($0.29) ($0.12) ($0.06) ($0.28) ($0.08)
Gross Margin
Q4
00
NM
Q1
01
NM
Q2
01
100.0%
Q3
01
NM
Q4
01
NM
Revenue
Q4
00
$0
Q1
01
$0
Q2
01
$300
Q3
01
$0
Q4
01
$0
EPS Fully Diluted
Q4
00
0.29)
Q1
01 ($ 0.12)Q2
01
($ 0.06)
Q3
01
($ 0.28)
Q4
01
($ 0.08)
Excl. Extraordinary Items
Fully Diluted Avg. Shrs.
Millions
Q4
00
11.9
Q1
01
14.0
Q2
01
14.2
Q3
01
15.4
Q4
01
19.6
Pretax Margin
Q4
00
NM
Q1
01
NM
Q2
01
(305.0)%
Q3
01
NM
Q4
01
NM
EBITD Margin
Q4
00
NM
Q1
01
NM
Q2
01
(288.3)%
Q3
01
NM
Q4
01
NM
Quarterly Balance Sheet
Quarterly Financials Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Years are Fiscal Years
In Thousands (Currency is U.S. Dollars)
As of
Dec 31 2000
Q4 ’00
As of
Mar 31 2001
Q1 ’01
As of
Jun 30 2001
Q2 ’01
As of
Sep 30 2001
Q3 ’01
As of
Dec 31 2001
Q4 ’01
Prepared Saturday, April 27, 2002 Page 14
Assets
Cash/Equivalents $1,546 $334 $928 $319 $11
Cash Held Broker 357 97 0 0 0
Loan Rcvbl.-Officer 0 1,025 985 755 0
Account Receivable 75 75 20 40 44
Raw Materials 121 121 115 111 98
Prepaid Expenses 3 6 0 0 5
Total Current Assets $2,102 $1,658 $2,048 $1,225 $158
Property, Net $20 $80 $122 $116 $121
Patents/Trademarks 336 355 310 308 489
Total Assets $2,458 $2,093 $2,480 $1,649 $768
Liabilities
Payable/Accrued $397 $381 $551 $270 $602
Conv. Debentures 1,598 1,461 1,391 0 0
Total Current Liabs $1,995 $1,842 $1,942 $270 $602
Due to Stockholders $1,256 $1,267 $1,242 $1,267 $848
Deferred Royalty 207 207 207 207 207
Total Liabilities $3,458 $3,316 $3,391 $1,744 $1,657
Shareholder Equity
Common Stock $1 $1 $1 $2 $2
Paid in Capital 8,812 10,259 11,486 16,537 17,964
Accum. Deficit (9,815) (11,483) (12,398) (16,633) (18,214)
Loan Rcvvl-Officers 0 0 0 0 (640)
Total Equity ($1,002) ($1,223) ($911) ($94) ($888)
Total Liab. & Sh. Equity $2,456 $2,093 $2,480 $1,650 $769
Shares Outstanding 13,999 14,289 14,848 19,516 19,785
Total Cash and Equivs.
Q4
00
$1,903
Q1
01
$431
Q2
01
$928
Q3
01
$319
Q4
01
$11
Total Liabilities
Q4
00
$3,458
Q1
01
$3,316
Q2
01
$3,391
Q3
01
$1,744
Q4
01
$1,657
Total Equity
Q4
00
($ 1,002)
Q1
01
($ 1,223)
Q2
01
($ 911)
Q3
01
($ 94)
Q4
01
($ 888)
Shares Outstanding
Millions
Q4
00
14.0
Q1
01
14.3
Q2
01
14.8
Q3
01
19.5 Q4
01
19.8
Quarterly Cash Flow Statement
Quarterly Financials Market Guide / ProVestor Plus Company Report
L.A.M. Pharmaceutical
(OTC:LAMP)
Years are Fiscal Years
In Thousands of U.S. Dollars
12 Months
Dec 31 2000
Q4 ’00
3 Months
Mar 31 2001
Q1 ’01
6 Months
Jun 30 2001
Q2 ’01
9 Months
Sep 30 2001
Q3 ’01
12 Months
Dec 31 2001
Q4 ’01
Prepared Saturday, April 27, 2002 Page 15
Cash From (Used By) Operations
Net Income ($4,777) ($1,668) ($2,582) ($6,818) ($8,399)
Depreciation 36 7 18 28 27
Options/Awards 448 10 96 3,554 4,266
Warrants Issued-LOC 0 1,100 1,100 1,100 1,100
Interest Expense 108 27 55 86 113
Conversion Premium 2,395 0 0 777 1,058
Stock Compensation 0 0 300 0 0
Investor Relations 0 0 319 0 0
Non-Cash Items 0 0 0 (93) 0
Accounts Receivable 0 0 54 35 31
Notes Receivable 50 0 0 0 0
Inventory (121) 0 6 10 23
Prepaid Expenses (3) (4) 3 3 (3)
Payable/Accrued 151 55 225 (57) 204
Due to Stockholder 0 0 (25) 0 0
Int.-Converted Debt 151 0 0 0 121
Cash From Operations ($1,562) ($473) ($431) ($1,375) ($1,459)
Plus: Cash From (Used by) Investment Activities
Capital Expenditures ($38) ($61) ($85) $0 ($113)
Patents/Trademarks (117) (25) (9) (3) (169)
Loans To Officer 0 (1,025) (985) 0 0
Cash From Investing ($155) ($1,111) ($1,079) ($3) ($282)
Plus: Cash From (Used By) Financing Activities
Convertible Debt 2,406 0 (60) (47) (109)
Exercise Options 189 112 112 112 112
Equity LOC 0 0 484 484 484
Loan Receivable 0 0 0 (755) (640)
Cash From Financing $2,595 $112 $536 ($206) ($153)
Equals: Increase (Decrease) In Cash
Net Change In Cash $879 ($1,472) ($974) ($1,584) ($1,892)
Free Cash Flow ($1,600) ($534) ($516) ($1,375) ($1,572)
Cash From Operations
Q4
00
($ 1,562)
Q1
01
($ 473)
Q2
01
($ 431)
Q3
01
($ 1,375)
Q4
01
($ 1,459)
Total Capital Expend.
Q4
00
($ 38)
Q1
01
($ 61)
Q2
01
($ 85)
Q3
01
$0
Q4
01
($ 113)
Cash From Financing
Q4
00
$2,595
Q1
01
$112
Q2
01
$536
Q3
01
($ 206)
Q4
01
($ 153)
Net Change In Cash
Q4
00
$879
Q1
01
($ 1,472)
Q2
01
($ 974)
Q3
01 ($ 1,584)
Q4
01
($ 1,892)

[js200]

@ MORCHEL

Was hälst du von BB:ENDV ???

Scheint ne schöne UNTERTASSE zu formen, was meinst du???

Schätze da sind auch ein paar Prozente drin, oder ???

JS200

[morchel]

So mal nachschauen was sich diese Woche getan hat!

LAMP
NKCIF naja
UDAT
GBSV naja
QNTI Volumen!
ETEN aber mit Anlass zur Hoffnung
DML.V naja
FXSO
OPTG naja
APTD